Identifying heart failure with preserved ejection fraction in Denmark
Official title: CoPenhagen Heart Failure With Preserved Ejection Fraction (CPH-HFpEF)
Run by Herlev and Gentofte Hospital · NCT06685237 · Data updated 2026-11-12
This study is trying to find and screen older adults in Denmark who are at risk for heart failure with preserved ejection fraction to better understand how to identify this condition and help those who might be affected.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 89 Years |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Herlev and Gentofte Hospital Academic / other |
| Locations | 1 site (Hellerup) |
| Status | Recruiting |
| Started | February 28, 2025 |
| Main results expected | November 28, 2025 |
| Study ends | March 28, 2026 |
| Registry record updated | March 5, 2025 |
| Trial ID | NCT06685237 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are Danish adults aged 50 years and older with at least two risk factors for HFpEF.
✕Probably not a fit
Patients who are younger than 50 years, have prevalent heart failure, or have significant comorbidities such as dementia or cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort study aims to identify and screen individuals at risk for heart failure with preserved ejection fraction (HFpEF) using data from the Danish National Health Registries. The study will recruit up to 5000 participants aged 50 and older from the Capital Region of Denmark who have at least two risk factors for HFpEF. Recruitment will be conducted through secure electronic communication to ensure privacy and efficiency. The study seeks to evaluate the effectiveness of identification and screening procedures for HFpEF and to understand barriers to participation among vulnerable populations.
Why it matters
Potential benefit: If successful, this study could lead to improved early identification and management of heart failure with preserved ejection fraction, potentially reducing morbidity and mortality rates.
How similar studies have gone: Other studies have shown success in identifying and managing heart failure with preserved ejection fraction, but this specific approach is novel in the Danish context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Residence in the Capital Region of Denmark 2. Age ≥ 50 years 3. At least two risk factors for HFpEF defined as any of the following (for age ≥ 60 years, only one): * Hypertension * Diabetes mellitus * Chronic kidney disease * Atrial fibrillation * BMI \> 25 kg/m2 * Previous heart valve surgery * Ischemic heart disease * Obstructive sleep apnea * Furosemide 40 mg Exclusion Criteria: 1. Age ≥ 90 years 2. Prevalent HF 3. Dementia 4. Nursing home 5. Amyloidosis 6. Hemodialysis 7. Cancer diagnosed within the past 5 years (skin cancer not included) 8. Prior solid organ transplantation 9. Lung disease defined as any of the following: * World Health Organization Group 1 pulmonary hypertension * Chronic pulmonary embolism * Lung fibrosis * Chronic obstructive pulmonary disease (COPD) * Home oxygen
Where it's running
-
Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital
Hellerup, Denmark Recruiting
Study contacts
- Study coordinator: Camilla I Ottosen, MD
- Email: camilla.ikast.ottosen@regionh.dk
- Phone: +4538674143
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF
This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.
-
Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease
This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.
-
Optimised Cardio-Renal Care for CKD and heart disease
This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.
-
Resmetirom for MASH with HFpEF in adults
This study tests whether resmetirom can be given safely and show liver-related effects in adults with MASH and heart failure with preserved ejection fraction over 24 weeks.
-
Elecoglipron vs placebo for adults with HFpEF or HFmrEF
This Phase 3 study tests whether elecoglipron helps people with HFpEF or HFmrEF who are on dapagliflozin and standard care.
-
Iron infusion and MRI to study inflammation in HFpEF
A small early-phase study tests whether an iron infusion affects heart inflammation in people with HFpEF, using MRI measures before and after treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.